Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression of ATF2.

Sha Xiao, Lu Guo, Ming Zhang, Rong Hu, Rong Liu

Endocrine, metabolic & immune disorders drug targets 2023

filter terms:

To explore the ATF2 expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients. Preeclampsia is a severe pregnancy-related hypertension disorder and refers to hypertension. This study was designed to explore the activating transcription factor 2 (ATF2) expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients. Firstly, we collected the plasma of normal and preeclampsia pregnancies and quantified the expressions of ATF2 by ELISA. Then we quantified the expression of the three downstream target genes of ATF2 (IL-8, IL-6 and MMP-2). Finally, we collected and quantified the interventional and observational group plasma. All data were compared by t-test (p<0.05). ATF2 and its target genes (IL-6, IL-8 and MMP-2) were upregulated in preeclampsia patients. In addition, ATF2 and its target genes were downregulated in the interventional group (LDA-treated group). Our results indicated that LDA could inhibit ATF2 expression in preeclampsia. It suggests that ATF2 may be a potential target of LDA in the prevention of preeclampsia. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Sha Xiao, Lu Guo, Ming Zhang, Rong Hu, Rong Liu. Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression of ATF2. Endocrine, metabolic & immune disorders drug targets. 2023;23(5):702-710